Literature DB >> 14996305

Detection of gender difference and epitope specificity of IgG antibody activity against IgA1 hinge portion in IgA nephropathy patients by using synthetic hinge peptide and glycopeptide probes.

Ikuko Nakamura1, Hitoo Iwase, Kenji Arai, Yoko Nagai, Kazunori Toma, Tadashi Katsumata, Yoshiyuki Hiki, Tohru Kokubo, Takashi Sano, Yutaka Kobayashi.   

Abstract

BACKGROUND AND AIMS: There are many reports on the presence of an incompletely glycosylated O-linked oligosaccharide(s) on the IgA1 hinge region in some immunoglobulin (IgA) nephropathy patients. Furthermore, the production of an antibody against the naked hinge peptide portion was reported in an IgA nephropathy patient. In this report, characterization of the IgG antibody against the hinge portion was carried out by using synthetic hinge glycopeptide probes. METHODS AND
RESULTS: The following synthetic hinge peptide and glycopeptides were prepared: 19mer peptide, V-P-S-T-P-P-T-P-S-P-S-T-P-P-T-P-S-P-S (designated HP), the peptide having a single alpha-linked GalNAc residue at positions 4, 7, 9, 11 and 15 (4 GN - 15 GN, respectively) and the same peptide having five GalNAc residues at all five positions (GN5). The mean value of the antibody activity against these probes was compared with each other. The highest activity against the naked hinge peptide (HP) and lowest activity against the fully glycosylated hinge peptide (GN5) were obvious. As attachment of GalNAc to position 4 or 11 on the peptide brought about a significant reduction of the activity against the naked hinge peptide, the P-S-T-P sequence included in both positions was thought to be the most probable site recognized by these antibodies. As an additional unexpected observation, a gender difference in this antibody activity against all the probes was found. The antibody activity in a female was significantly higher compared with that in a male.
CONCLUSION: Because the frequency of incidence of IgA nephropathy is known to be slightly higher in males, this gender difference might indicate a protective meaning to remove aberrantly glycosylated molecules from the patient's serum.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996305     DOI: 10.1111/j.1440-1797.2003.00225.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  6 in total

1.  The glycans deficiencies of macromolecular IgA1 is a contributory factor of variable pathological phenotypes of IgA nephropathy.

Authors:  L-X Xu; Y Yan; J-J Zhang; Y Zhang; M-H Zhao
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

2.  Differential binding characteristics of native monomeric and polymeric immunoglobulin A1 (IgA1) on human mesangial cells and the influence of in vitro deglycosylation of IgA1 molecules.

Authors:  Y-H Gao; L-X Xu; J-J Zhang; Y Zhang; M-H Zhao; H-Y Wang
Journal:  Clin Exp Immunol       Date:  2007-03-26       Impact factor: 4.330

Review 3.  The Phenotypic Difference of IgA Nephropathy and its Race/Gender-dependent Molecular Mechanisms.

Authors:  Yusuke Suzuki; Renato C Monteiro; Rosanna Coppo; Hitoshi Suzuki
Journal:  Kidney360       Date:  2021-05-28

Review 4.  Immunopathogenesis of IgAN.

Authors:  Jonathan Barratt; Alice C Smith; Karen Molyneux; John Feehally
Journal:  Semin Immunopathol       Date:  2007-09-13       Impact factor: 9.623

5.  Protective role of anti-synthetic hinge peptide antibody for glomerular deposition of hypoglycosylated IgA1.

Authors:  Yoshiyuki Hiki; Kazuo Takahashi; Sachiko Shimozato; Hiroko Odani; Kouichirou Yamamoto; Makoto Tomita; Midori Hasegawa; Kazutaka Murakami; Kunihiro Nabeshima; Shigeru Nakai; Yoshiroh Fujita; Isao Ishida; Hitoo Iwase; Satoshi Sugiyama
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

6.  Specificity of two monoclonal antibodies against a synthetic glycopeptide, an analogue to the hypo-galactosylated IgA1 hinge region.

Authors:  Yoshiyuki Hiki; Hideo Hori; Kouichiro Yamamoto; Yoshihiro Yamamoto; Yukio Yuzawa; Nobuya Kitaguchi; Kazuo Takahashi
Journal:  J Nephrol       Date:  2014-07-19       Impact factor: 3.902

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.